MARKET

BCYC

BCYC

Bicycle Therapeutics Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.01
+0.62
+3.37%
Closed 16:00 09/25 EDT
OPEN
18.39
PREV CLOSE
18.39
HIGH
19.67
LOW
18.38
VOLUME
24.32K
TURNOVER
--
52 WEEK HIGH
21.59
52 WEEK LOW
7.50
MARKET CAP
366.60M
P/E (TTM)
-9.1654
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Revenue Downgrade: Here's What Analysts Forecast For Bicycle Therapeutics plc (NASDAQ:BCYC)
Market forces rained on the parade of Bicycle Therapeutics plc (NASDAQ:BCYC) shareholders today, when the analysts...
Simply Wall St. · 6d ago
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
Bicycle Therapeutics to Present Trials in Progress Poster for BT8009 at the ESMO Virtual Congress 2020
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that a poster describing the design of the ongoing Phase I/II trial of BT8009 will be presented during
Business Wire · 09/14 11:59
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase
Business Wire · 09/10 21:05
Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following virtual investor conferences in September:
Business Wire · 09/03 11:59
Bicycle Therapeutics lead drug advances in solid tumor study
The first participant has been dosed in a the Phase 2a expansion portion of a Phase 1/2a clinical trial evaluating Bicycle Therapeutics' (BCYC) lead candidate BT1718 in patients with MT1-MMP-positive
Seekingalpha · 09/02 11:13
Bicycle Therapeutics Announces First Patient Dosed In Phase IIa Trial Of Bicycle Toxin Conjugate BT1718
- Two cohorts have been initiated: a squamous non-small cell lung cancer cohort and a solid tumor “basket” cohort; up to two additional cohorts may be added based on preliminary results - Patients will be
Two cohorts have been initiated: a squamous non-small cell lung cancer cohort and a solid tumor “basket” cohort; up to two additional cohorts may be added based on preliminary results - Patients will be · 09/02 10:59
Bicycle Therapeutics Announces First Patient Dosed in Oxurions Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
Business Wire · 09/01 11:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCYC. Analyze the recent business situations of Bicycle Therapeutics Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCYC stock price target is 24.86 with a high estimate of 30.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 24
Institutional Holdings: 7.28M
% Owned: 37.74%
Shares Outstanding: 19.28M
TypeInstitutionsShares
Increased
4
93.19K
New
6
232.18K
Decreased
2
14.89K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BCYC
Bicycle Therapeutics PLC, formerly Bicycle Therapeutics Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The Company is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The Company is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Bicycle Therapeutics PLC (ADR) stock information, including NASDAQ:BCYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCYC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCYC stock methods without spending real money on the virtual paper trading platform.